288 related articles for article (PubMed ID: 35959282)
1. Mesenchymal Stem Cell Derived Exosomes as Nanodrug Carrier of Doxorubicin for Targeted Osteosarcoma Therapy via SDF1-CXCR4 Axis.
Wei H; Chen F; Chen J; Lin H; Wang S; Wang Y; Wu C; Lin J; Zhong G
Int J Nanomedicine; 2022; 17():3483-3495. PubMed ID: 35959282
[TBL] [Abstract][Full Text] [Related]
2. A Nanodrug Consisting Of Doxorubicin And Exosome Derived From Mesenchymal Stem Cells For Osteosarcoma Treatment In Vitro.
Wei H; Chen J; Wang S; Fu F; Zhu X; Wu C; Liu Z; Zhong G; Lin J
Int J Nanomedicine; 2019; 14():8603-8610. PubMed ID: 31802872
[TBL] [Abstract][Full Text] [Related]
3. Exosome mimetics derived from bone marrow mesenchymal stem cells ablate neuroblastoma tumor in vitro and in vivo.
Li M; Wang J; Guo P; Jin L; Tan X; Zhang Z; Zhanghuang C; Mi T; Liu J; Wang Z; Wu X; Wei G; He D
Biomater Adv; 2022 Nov; 142():213161. PubMed ID: 36308859
[TBL] [Abstract][Full Text] [Related]
4. Exosome mimetics derived from bone marrow mesenchymal stem cells deliver doxorubicin to osteosarcoma
Wang J; Li M; Jin L; Guo P; Zhang Z; Zhanghuang C; Tan X; Mi T; Liu J; Wu X; Wei G; He D
Drug Deliv; 2022 Dec; 29(1):3291-3303. PubMed ID: 36352741
[TBL] [Abstract][Full Text] [Related]
5. Targeted doxorubicin-loaded mesenchymal stem cells-derived exosomes as a versatile platform for fighting against colorectal cancer.
Bagheri E; Abnous K; Farzad SA; Taghdisi SM; Ramezani M; Alibolandi M
Life Sci; 2020 Nov; 261():118369. PubMed ID: 32882265
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Glioma Cells' Proliferation by Doxorubicin-Loaded Exosomes via Microfluidics.
Thakur A; Sidu RK; Zou H; Alam MK; Yang M; Lee Y
Int J Nanomedicine; 2020; 15():8331-8343. PubMed ID: 33149579
[TBL] [Abstract][Full Text] [Related]
7. MiR-199a-modified exosomes from adipose tissue-derived mesenchymal stem cells improve hepatocellular carcinoma chemosensitivity through mTOR pathway.
Lou G; Chen L; Xia C; Wang W; Qi J; Li A; Zhao L; Chen Z; Zheng M; Liu Y
J Exp Clin Cancer Res; 2020 Jan; 39(1):4. PubMed ID: 31898515
[TBL] [Abstract][Full Text] [Related]
8. AS1411 aptamer-functionalized exosomes in the targeted delivery of doxorubicin in fighting colorectal cancer.
Hosseini NF; Amini R; Ramezani M; Saidijam M; Hashemi SM; Najafi R
Biomed Pharmacother; 2022 Nov; 155():113690. PubMed ID: 36099793
[TBL] [Abstract][Full Text] [Related]
9. Activation of Dynamin-Related Protein 1 and Induction of Mitochondrial Apoptosis by Exosome-Rifampicin Nanoparticles Exerts Anti-Osteosarcoma Effect.
Chen W; Lin W; Yu N; Zhang L; Wu Z; Chen Y; Li Z; Gong F; Li N; Chen X; He X; Wu Y; Zeng X; Yueh Y; Xu R; Ji G
Int J Nanomedicine; 2022; 17():5431-5446. PubMed ID: 36426375
[TBL] [Abstract][Full Text] [Related]
10. Exosomal LncRNA-NEAT1 derived from MIF-treated mesenchymal stem cells protected against doxorubicin-induced cardiac senescence through sponging miR-221-3p.
Zhuang L; Xia W; Chen D; Ye Y; Hu T; Li S; Hou M
J Nanobiotechnology; 2020 Oct; 18(1):157. PubMed ID: 33129330
[TBL] [Abstract][Full Text] [Related]
11. Application of tumor-targeting peptide-decorated polypeptide nanoparticles with doxorubicin to treat osteosarcoma.
Qiu R; Sun D; Bai Y; Li J; Wang L
Drug Deliv; 2020 Nov; 27(1):1704-1717. PubMed ID: 33305647
[TBL] [Abstract][Full Text] [Related]
12. Effect of platelet exosomes loaded with doxorubicin as a targeted therapy on triple-negative breast cancer cells.
Uslu D; Abas BI; Demirbolat GM; Cevik O
Mol Divers; 2024 Apr; 28(2):449-460. PubMed ID: 36576666
[TBL] [Abstract][Full Text] [Related]
13. Multimodal transfer of MDR by exosomes in human osteosarcoma.
Torreggiani E; Roncuzzi L; Perut F; Zini N; Baldini N
Int J Oncol; 2016 Jul; 49(1):189-96. PubMed ID: 27176642
[TBL] [Abstract][Full Text] [Related]
14. Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy.
Li Y; Hou H; Zhang P; Zhang Z
Drug Deliv; 2020 Dec; 27(1):1044-1053. PubMed ID: 32633576
[TBL] [Abstract][Full Text] [Related]
15. Exosomes miRNA-499a-5p targeted CD38 to alleviate anthraquinone induced cardiotoxicity: experimental research.
Ma C; Yang Z; Wang J; She H; Tan L; Ye Q; Wang F; Feng X; Mo X; Liu K; Liu L
Int J Surg; 2024 Apr; 110(4):1992-2006. PubMed ID: 38277348
[TBL] [Abstract][Full Text] [Related]
16. Pioglitazone modulates doxorubicin resistance in a in vivo model of drug resistant osteosarcoma xenograft.
Natarajan A; Ramachandran B; Gopisetty G; Jayavelu S; Sundersingh S; Rajkumar T
Naunyn Schmiedebergs Arch Pharmacol; 2021 Feb; 394(2):361-371. PubMed ID: 33015747
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal stem cell-derived exosomes carrying microRNA-150 suppresses the proliferation and migration of osteosarcoma cells via targeting IGF2BP1.
Xu Z; Zhou X; Wu J; Cui X; Wang M; Wang X; Gao Z
Transl Cancer Res; 2020 Sep; 9(9):5323-5335. PubMed ID: 35117898
[TBL] [Abstract][Full Text] [Related]
18. Increased anti-tumour activity by exosomes derived from doxorubicin-treated tumour cells via heat stress.
Yang Y; Chen Y; Zhang F; Zhao Q; Zhong H
Int J Hyperthermia; 2015; 31(5):498-506. PubMed ID: 25955015
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow mesenchymal stem cells and their derived exosomes resolve doxorubicin-induced chemobrain: critical role of their miRNA cargo.
El-Derany MO; Noureldein MH
Stem Cell Res Ther; 2021 Jun; 12(1):322. PubMed ID: 34090498
[TBL] [Abstract][Full Text] [Related]
20. Estrogen-functionalized liposomes grafted with glutathione-responsive sheddable chotooligosaccharides for the therapy of osteosarcoma.
Yin X; Feng S; Chi Y; Liu J; Sun K; Guo C; Wu Z
Drug Deliv; 2018 Nov; 25(1):900-908. PubMed ID: 29644882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
